Evidence map›Paper›PMID 32236688›Full record

ReviewDer Urologe. Ausg. A2020

[The Alken stages-a German-French affair].

Friedrich H Moll, Matthias Oelke

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Friedrich H MollInstitut für Geschichte, Theorie und Ethik der Medizin, Heinrich-Heine-Universität, Düsseldorf, Deutschland. friedrich.moll@uni-koeln.de.
Matthias OelkeKlinik für Urologie, Kinderurologie und Urologische Onkologie, St. Antonius-Hospital GmbH, Gronau, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anatomy and pathophysiology of the prostate have gained increasing attention of anatomists and surgeons at the beginning of the 19th century. It was only around 1900 that French and German authors discussed staging of clinical benign prostatic hyperplasia (BPH) in order to group therapy. From 1970 to the 1990s, staging of the clinical course of BPH was associated with the name of Carl-Erich Alken, a leading figure within the German urological society at that time, although Alken never researched or focused on disease staging. He only presented the three traditional clinical stages originally described in 1888 by Jean Casimir Felix Guyon in a short and often edited and translated student's textbook (1955).

Indexed as

Prostatic HyperplasiaHumansMaleBenign prostate hyperplasiaC.-E. AlkenEponymsHistory of medicineHistory of urologyStaging according to Alken

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.